Phase 4 N=4,447 PrEP Implementation for Mothers in Antenatal Care
HIV Infections · Pregnancy Related
Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=60 A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department
Conscious Sedation · Simple Lacerations Less Than 4 cm · Lumbar Punctures
Primary: ED Length of Stay After Intranasal Midazolam or Nitrous Oxide Administration — 24.5; 18.5; 9; 10 minutes
Phase 4 N=20 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
Central Centrifugal Cicatricial Alopecia
Primary: Mean Change in Physician Global Assessment of Improvement (PGA-I) — 0.07 score on a scale
Phase 4 N=1,409 Post-Discharge Smoking Cessation Strategies: Helping HAND 4
Smoking Cessation
Primary: Tobacco Abstinence, Biochemically Confirmed — 110; 96 Participants — p=.19
Phase 4 N=40 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
Congestive Heart Failure
Primary: Change in Body Weight at 48 Hours — -3.3; -0.8 pounds — p=0.094
Phase 4 N=662 Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
Multiple Sclerosis (MS)
Primary: Percentage of Participants Using Wheelchair or Being Bedridden Assessed by Expanded Disability Status Scale (EDSS) Score 7.0 or Higher — 8.2 percentage of participant
Phase 4 N=323 Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
Spondyloarthritis
Primary: Percentage of Participants Without a Disease Activity Flare During Period 2 — 84.1; 68.3; 33.9 Percentage of participants — p=<0.001
Phase 4 N=120 Nebulized Sub-dissociative Dose Ketamine for Treating Pain
Pain
Primary: Change in Pain Scores From Baseline to 30 Minutes — 4.0; 4.2; 4.1 units on a scale
Phase 4 N=14 Sleep and Breathing in the General Population - Chemical Stimuli
Sleep-disordered Breathing
Primary: The Central Apnea-hypopnea Index — 14.1; 29.9 events per hour
Phase 4 N=50 Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients
Cardiovascular Risk Factor
Primary: LDL-C at Month 3 — 145 mg/dL — p=0.03
Phase 4 N=7 The Effectiveness of Kuvan in Amish PKU Patients
Phenylketonuria
Primary: Number of Participants With 20% Decrease in Phenylalanine Levels From Baseline (Positive Response) — 0; 0; 0 Participants
Phase 4 N=160 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
Joint Disease · Pain, Acute · Pain, Chronic
Primary: Opioid Use — 288; 432.5 Oral Morphine Equivalent (mg)
Phase 4 N=25 Contact: Developing New Clinical Management Strategies
Major Depressive Disorder
Primary: Change From Baseline Hamilton Rating Scale for Depression 24-Item Scale to Study Completion (8 Weeks) — 1.33; 11.4; 5.33; 9.25 score on a scale — p=0.292
Phase 4 N=161 Assessing Efficacy of Intravenous Acetaminophen for Perioperative Pain Control for Oocyte Retrieval
Infertility, Female · Pain, Postoperative
Primary: Post-operative Pain Score Difference 10 Mins From Pre-operative — 1.3; 1.3; 1.8 score on a scale
Phase 4 N=100 HIV Non-Occupational Post-Exposure Prophylaxis
Human Immunodeficiency Virus
Primary: Number of Adverse Event Occurrences — 38; 28; 28; 14 events